Septin9 gene methylation detection primer probe system and kit thereof
Through the Septin9 gene methylation detection primer probe system and ddPCR method, peripheral venous blood extraction is used to achieve non-invasive and highly sensitive early screening of colorectal cancer, solving the invasiveness and detection accuracy of colorectal cancer diagnosis methods in the existing technology. The problem provides an efficient and accurate detection solution.
Patent Information
- Application Number
- CN202411453923.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-10-17
- Publication Date
- 2024-11-26
AI Technical Summary
Existing diagnostic methods for colorectal cancer, such as colonoscopy, and poor sensitivity and specificity of fecal occult blood detection, which cannot meet the needs of early screening, especially for the detection of abnormal methylation of Septin9 gene.
Develop a Septin9 gene methylation detection primer probe system and its kit. By using ddPCR detection method, it provides a non-invasive and highly sensitive early screening solution, including amplified primer pairs and probe a, Probe a', differentiated methylated and unmethylated states using different reporter fluorophores.
A non-invasive, fast and accurate Septin9 gene methylation detection is achieved, reducing the false positive and false negative rates, improving the sensitivity and specificity of the detection, suitable for a wide range of people, and avoiding the discomfort and risks caused by invasive operations.
Smart Images

Figure CN119020496A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biotechnology, and particularly relates to a Septin9 gene methylation detection primer probe system and a kit thereof. Background Art
[0002] The Sept family is a group of highly conserved GTP-binding proteins that are widely present in human cells and provide structural support during cell division. The Septin9 gene is a member of the SEPT gene family and is located on human chromosome 17q25.3. It is one of the genes that regulate normal cell growth. The protein it encodes is located in the cytoplasm and is a highly glycosylated protein. It is a downstream signal of p53-mediated cell cycle regulation, which can cause abnormal cells to arrest in the G2 phase and prevent cell proliferation. Abnormal methylation of the Septin9 promoter can inhibit transcription, cause disorders in G2 / M checkpoint regulation, and lead to abnormal cell proliferation. It plays an important role in multiple biological processes such as cytoplasmic division, cell polarization, vesicle transport, and cell membrane construction.
[0003] SEPT9 is involved in actin dynamics, cytoskeleton remodeling, vesicle transport and exocytosis by encoding GTP-binding proteins. The level of methylated SEPT9 (mSEPT9) is low in healthy tissues, but significantly increased in pathological tissues such as colorectal cancer. Therefore, colorectal cancer patients can be identified by detecting the level of mSEPT9 in plasma. Colorectal cancer (CRC) is a common gastrointestinal malignancy. Epidemiological survey data worldwide show that the incidence of colorectal cancer ranks third among all types of malignant tumors. It is a common digestive tract malignancy, ranking second in gastrointestinal tumors; the incidence of rectal cancer is second only to gastric and esophageal cancer. With the change of people's living habits, the incidence and mortality of colorectal cancer have increased significantly, which seriously threatens human health. The early symptoms of colorectal cancer are not obvious. As the tumor grows, it shows symptoms such as changes in bowel habits, blood in the stool, diarrhea, alternating diarrhea and constipation, local abdominal pain, etc., and in the late stage, it develops into systemic symptoms such as anemia and weight loss. The detection target of the CRC early diagnosis kit is the SEPT-V2 region. Abnormally methylated Septin9 gene is not only present in colorectal cancer tissues and peripheral blood of patients, but also closely related to breast cancer, ovarian cancer, leukemia and lymphoma. In addition, among the seven high-frequency methylated genes found in the plasma of colorectal cancer patients, including APC, SHP1, E-cadherin, ER, Septin9, SEMA3B and 3OST2, only the Septin9 gene is significantly low-frequency methylated in the plasma of non-colorectal cancer patients, which indicates that Septin9 can be used as an early tumor marker for colorectal cancer. On the other hand, enhancing the expression of Septin9 mRNA and protein by using demethylating agents can make tumor suppressor genes regain their function, and the interference of Septin9 may reduce the occurrence of abnormal methylation of Septin9, and the combined use of histone deacetylase inhibitors has a more significant effect on inhibiting tumor cell growth.
[0004] DNA methylation refers to the covalent binding of the methyl group (-CH3) of S-adenosylmethionine to the 5-carbon atom of the cytosine (C) base of the DNA molecule under the action of DNA methyltransferase to form 5-methylcytosine (5mC) without changing the DNA sequence. Numerous studies have shown that SEPT9 gene promoter methylation is closely related to the occurrence and development of colorectal cancer, and it is a specific molecular marker for colorectal cancer. Therefore, detecting the methylation status of the SEPT9 gene promoter in colorectal cancer is of great significance for the diagnosis, treatment, and prognosis of colorectal cancer.
[0005] Although colonoscopy is a standard method for identifying and removing colorectal lesions (including polyps), it is invasive and uncomfortable. Patients need to prepare their bowels and empty their intestines, which may cause discomfort and burden to patients. In addition, colonoscopy may also cause complications such as bleeding or perforation, further increasing the risk to patients. Fecal occult blood testing is a non-invasive screening method, but its sensitivity and specificity are not ideal. It may not detect all cases of colorectal cancer and may produce false positive results due to factors such as diet and medication. Therefore, new products need to be developed to meet market needs. Summary of the invention
[0006] Technical problems to be solved: In response to the above technical problems, the present invention provides a Septin9 gene methylation detection primer probe system and a kit thereof, which only requires the extraction of peripheral venous blood, so the patient compliance is relatively high; the ddPCR detection method is used, which is non-invasive for early screening of colorectal cancer and has high detection sensitivity.
[0007] Technical solution: In the first aspect, the present invention provides a Septin9 gene methylation detection primer probe system, comprising an amplification primer pair, a probe a for detecting methylated genes, and a probe a' for detecting unmethylated genes; the amplification primer pair comprises an upstream primer and a downstream primer, and the nucleotide sequence thereof is shown in SEQ ID NO.1-SEQ ID NO.2, the nucleotide sequence of probe a is shown in SEQ ID NO.3, and the nucleotide sequence of probe a' is shown in SEQ ID NO.4; the 5' ends of the probe a and the probe a' are provided with different reporter fluorescent groups: SEQ ID NO.1: TGGTGGGGGTGTAGTTGTAG; SEQ ID NO.2: ACAACCAAACAAAATTCTCTATCACC; SEQ ID NO.3: TTAATTTTTGTAGGCGTAGAG; SEQ ID NO.4: GTTTAATTTTTGTAGGTGTAGAG.
[0008] Preferably, the final concentration of each primer used in the PCR reaction is 900 nM, and the final concentration of each probe used in the PCR reaction is 250 nM.
[0009] Preferably, the reporter fluorescent group is FAM or VIC.
[0010] Preferably, the probability of SEPTIN9 gene methylation = the number of copies of the fluorescence carried by the reporter probe a ÷ (the number of copies of the fluorescence carried by the reporter probe a + the number of copies of the fluorescence carried by the reporter probe a').
[0011] In a second aspect, the present invention provides a SEPTIN9 gene methylation detection kit comprising the primer-probe system described in the first aspect.
[0012] Beneficial effects: The Septin9 gene methylation detection primer probe system and kit of the present invention only require the extraction of peripheral venous blood, so the patient compliance is high; the ddPCR detection method is non-invasive for early screening of colorectal cancer and has high detection sensitivity. The kit of the present invention is relatively quick to operate, avoids the discomfort and risks caused by invasive operations, can accurately identify, reduce the occurrence of false positives and false negatives, and is suitable for a wide range of people. BRIEF DESCRIPTION OF THE DRAWINGS
[0013] Figure 1 is a schematic diagram of the detection results of sample 1 in Example 1 of the present invention, where the horizontal axis is HEX and the vertical axis is FAM; Figure 2 It is a schematic diagram of the detection results of sample 2 in Example 1 of the present invention, where the horizontal axis is HEX and the vertical axis is FAM. DETAILED DESCRIPTION
[0014] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments: Example 1
[0015] The steps of using the primer-probe system of the present invention to detect the methylation probability of the sample to be tested (the sample verified by pyrophosphate sequencing and BSP sequencing) are as follows: 1. Pretreatment of the sample to be tested: Use a DNA methylation modification kit (EZ DNA Methylation-Lightning, KitZYMO RESEARCH) to treat the DNA of the sample to be tested with sulfite to obtain a sulfite-treated sample; 2. Synthesize primers and probes: According to the sequence in Table 1 below, entrust Nanjing Kebai Biotechnology Co., Ltd. to complete the synthesis.
[0016] Table 1 Primer-probe system of the present invention
[0017] Note: The 5' end of the probe SEPTIN9-P-M4 is modified with FAM, and the 5' end of the probe SEPTIN9-P-UM4 is modified with HEX.
[0018] 3. Use Bio-Rad's ddPCR supermix for probes to test the samples after sulfite treatment: 3.1. Prepare the PCR reaction system as shown in Table 2 below: Table 2 PCR reaction system
[0019] Note: The concentration of the DNA after sulfite treatment is 50 ng / μL, the concentrations of the upstream primer and the downstream primer in the amplification primer pair are both 900 nM, and the concentrations of probes a and a' are both 250 nM.
[0020] 3.2. The setting of the reaction program is shown in Table 3 below: Table 3 PCR reaction procedure
[0021] Note: The heating rate is 2°C / sec., the cover temperature is set to 105°C, and the sample volume is set to 40 μL.
[0022] 3.3 Results and Analysis The experimental results are as follows Figure 1-Figure 2 The corresponding data are shown in Table 4 below: Table 4 Experimental results
[0023] Among them, sample 1 is a known methylated sample, and sample 2 is a known unmethylated sample.
[0024] The results show that the method of the present invention can directly quantify the methylation probability, has higher efficiency, and the data is more intuitive. In addition, compared with other sequencing methods, the method of the present invention takes less time and is more efficient. Example 2
[0025] The positive samples and negative samples were mixed in different proportions, and the primer-probe system of the present invention was used for detection according to Example 1, as shown in Table 5 below: Table 5 Sample combinations with different proportions and test results
[0026] The results show that the probe of the present invention exhibits high specificity and appropriate sensitivity during the detection process and is capable of detecting the target substance in the positive sample. Example 3
[0027] Low-frequency samples were prepared and tested using the primer-probe system of the present invention according to Example 1. The results are shown in Table 6 below: Table 6 Low frequency samples and their detection results
[0028] As shown in Table 6, the error between the theoretical value and the actual value is within 5%, and the sensitivity and specificity of the primer probe are relatively ideal, which can accurately reflect the situation of the sample. Furthermore, even for low-copy and low-concentration samples, the accuracy and sensitivity of the detection can be guaranteed.
[0029] In molecular biology experiments, the sensitivity and specificity of primer probes are two key indicators for evaluating the experimental results. Sensitivity refers to the ability of the probe to correctly identify and amplify the target sequence (i.e., positive sample), while specificity refers to the ability of the probe not to react with non-target sequences (i.e., negative sample) during the amplification process.
[0030] When it is mentioned that "the error between the theoretical ratio and the actual detection ratio is within 5%, this usually means that the accuracy of the experimental results is very high and very close to the expected theoretical value. This high degree of accuracy can indirectly reflect that the sensitivity and specificity of the primer probe are relatively excellent.
[0031] Analysis process: Sensitivity analysis: If the sensitivity of the primer is not high, then even if the target sequence exists in the sample (positive sample), the actual positive ratio detected may be lower than the theoretical value due to insufficient amplification efficiency. However, since the error between the actual detection ratio and the theoretical ratio is within 5%, it means that the primer can efficiently amplify the target sequence, that is, the sensitivity is high; Specificity analysis: If the primers are not specific, they may react with non-target sequences (negative samples) during the amplification process, resulting in the actual positive ratio being higher than the theoretical value. However, the error between the actual detection ratio and the theoretical ratio is very small (within 5%), indicating that the primers hardly react with non-target sequences during the amplification process, that is, the specificity is very high.
[0032] Therefore, when the error between the theoretical ratio and the actual detection ratio is within 5%, it can be considered that the sensitivity and specificity of the primer probe are relatively excellent. This excellent performance enables the primer probe to distinguish the positive and negative proportions in the sample well, providing reliable data support for subsequent molecular biology experiments.
[0033] In summary, the experimental results not only verified the accuracy and reliability of the primer probe, but also further demonstrated its wide application value in molecular biology research.
[0034] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. SEPTIN9 gene methylation detection primer probe system, characterized in that: It includes an amplification primer pair, a probe a for detecting methylated genes, and a probe a' for detecting unmethylated genes; The amplification primer pair includes an upstream primer and a downstream primer, the nucleotide sequences of which are shown in SEQ ID NO.1-SEQ ID NO.2, the nucleotide sequence of probe a is shown in SEQ ID NO.3, and the nucleotide sequence of probe a' is shown in SEQ ID NO.4; The 5' ends of the probe a and the probe a' are provided with different reporter fluorescent groups.
2. The SEPTIN9 gene methylation detection primer-probe system according to claim 1, characterized in that: The final concentration of each primer used in the PCR reaction was 900 nM, and the final concentration of each probe used in the PCR reaction was 250 nM.
3. The SEPTIN9 gene methylation detection primer-probe system according to claim 1, characterized in that: The reporter fluorescent group is FAM or VIC.
4. The SEPTIN9 gene methylation detection primer-probe system according to claim 1, characterized in that: The probability of SEPTIN9 gene methylation = the number of copies of the fluorescence carried by reporter probe a ÷ (the number of copies of the fluorescence carried by reporter probe a + the number of copies of the fluorescence carried by reporter probe a').
5. A SEPTIN9 gene methylation detection kit comprising the primer-probe system according to any one of claims 1 to 4.
Citation Information
Patent Citations
Primer and kit for detecting septin9 gene methylation
CN106244724A
Gastric cancer gene methylation detection kit and detection method
CN117431320A
Method for detecting colorectal cancer DNA methylation and reagent
US20240271219A1
Cited By
Nucleic acid sequence molecule and DNA methylation detection method
CN120700139A
